Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,884 |
Ending reported balance
After 2026-09-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-22 · Exercise / conversion · Acquired 15,940 · Balance 62,443 Row 2 · 2026-09-22 · Tax withholding · Disposed 5,559 · Balance 56,884 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-26 | Direct | 0 |
Reported balance
After 2026-09-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-22 · Exercise / conversion · Disposed 15,940 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,511 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 24, 2026 20:52 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,940 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0000914190-26-000139 · form4.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,940 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:52 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 5,559 | $72.55 | $403,305.45 |
DisclosureSEC source: 0000914190-26-000139 · form4.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,884 Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:52 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 15,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000139 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000016 · form4.xml · derivative · entry 11 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000016 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,503 Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:09 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,040 | $0.00 Strike: $21.84 | $0.00 |
DisclosureSEC source: 0001062993-25-014992 · form4.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,040 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:09 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 17,040 | $56.21 | $957,818.40 |
DisclosureSEC source: 0001062993-25-014992 · form4.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,863 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.97 to $56.34 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:09 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 17,040 | $21.84 | $372,153.60 |
DisclosureSEC source: 0001062993-25-014992 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018027 · form4.xml · derivative · entry 11 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018027 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,863 Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001062993-24-014847 · form4.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 16,000 | $72.10 | $1,153,664.00 |
DisclosureSEC source: 0001062993-24-014847 · form4.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,401 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 16,000 | $22.95 | $367,200.00 |
DisclosureSEC source: 0001062993-24-014847 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:39 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019844 · form4.xml · derivative · entry 11 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:39 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019844 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,401 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010917 · form4-10312022_021035.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010917 · form4-10312022_021035.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,444 Read SEC document |
| May 10, 2022 Filed May 11, 2022 20:52 UTC | BIO-TECHNE Corp TECH · Entity 3479 | PurchaseCommon Stock | 300 | $352.55 | $105,765.00 |
DisclosureSEC source: 0001415889-22-004847 · form4-05112022_010505.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,106 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:43 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000401 · edgar.xml · derivative · entry 9 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:43 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000401 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,806 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (right to buy) · Derivative | 4,000 | $0.00 Strike: $87.39 | $0.00 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · derivative · entry 8 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $487.88 | $48,788.23 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 7 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.87 to $487.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 800 | $487.10 | $389,682.16 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 6 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,712 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.84 to $487.52, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,600 | $486.25 | $778,004.16 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 5 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,512 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.59 to $486.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 600 | $485.03 | $291,015.24 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 4 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,112 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.52 to $485.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 601 | $483.60 | $290,643.18 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,712 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.01 to $483.86, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 299 | $481.77 | $144,050.43 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,313 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.41 to $482.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,000 | $87.39 | $349,560.00 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (right to buy) · Derivative | 5,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0000914190-20-000424 · edgar.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $303.34 | $1,516,675.00 |
DisclosureSEC source: 0000914190-20-000424 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $66.90 | $334,500.00 |
DisclosureSEC source: 0000914190-20-000424 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006501 · primarydocument.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006501 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (right to Buy) · Derivative | 5,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · derivative · entry 6 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 125 | $267.94 | $33,492.58 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 5 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,221 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.82 to $267.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,974 | $267.32 | $527,685.34 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 4 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,346 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.82 to $267.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,601 | $266.07 | $425,979.03 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,320 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.68 to $266.6712, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,300 | $265.35 | $344,959.81 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,921 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.64 to $265.6276, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $70.35 | $351,750.00 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000009 · edgar.xml · derivative · entry 10 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000009 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,221 Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | PurchaseCommon Stock | 500 | $191.06 | $95,530.00 |
DisclosureSEC source: 0000914190-19-000261 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,726 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004303 · primarydocument.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:51 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004303 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,226 Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 21:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $61.46 | $0.00 |
DisclosureSEC source: 0001562180-18-003787 · primarydocument.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 21:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $188.47 | $942,333.50 |
DisclosureSEC source: 0001562180-18-003787 · primarydocument.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.17 to $188.73, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 21:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $61.46 | $307,300.00 |
DisclosureSEC source: 0001562180-18-003787 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to buy) · Derivative | 5,000 | $0.00 Strike: $63.03 | $0.00 |
DisclosureSEC source: 0001562180-17-003467 · primarydocument.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $130.18 | $650,907.00 |
DisclosureSEC source: 0001562180-17-003467 · primarydocument.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.24 to $131.85, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $63.03 | $315,150.00 |
DisclosureSEC source: 0001562180-17-003467 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.